Abstract
Patients (pts) with mCRC have few treatment options and poor outcome, particularly those with KRAS mutation (mKRAS). After failure of 1L treatment, the ORR for FOLFIRI/bev is 5-13%, with PFS 4-6 mos, and OS 10-12 mos. Onvansertib (Onv), is a highly specific PLK1 inhibitor, currently being investigated in combination with FOLFIRI/bev in 2L treatment of mKRAS mCRC (NCT03829410). Preliminary results indicate that Onv+ FOLFIRI/bev is well tolerated and efficacious (Lenz et al, JCO 2022). We investigated the utility of measuring early changes of KRAS MAF, using liquid biopsies, to predict clinical benefit to Onv+FOLFIRI/bev.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
